Composition and dosage form comprising an amphiphilic molecule as a suspension vehicle

• US 20050112188A1
• Filed: 11/15/2004
• Published: 05/26/2005
• Est. Priority Date: 11/17/2003
• Status: Active Grant

• Current Assignee: Intarcia Therapeutics, Inc.
• Original Assignee: Intarcia Therapeutics, Inc.
• Inventors: Zhang, Yuanpeng, Eliaz, Rom Ezer, Junnarkar, Gunjan, Weeks, Eric William, Rohloff, Catherine Manya
• Granted Patent: US 7,731,947 B2
• Time in Patent Office: Days
• US Class Current: 424/450
• CPC Class Codes: A61K 31/519 ortho- or peri-condensed with heterocyclic rings
• CPC Class Codes: A61K 38/21 Interferons [IFN]
• CPC Class Codes: A61K 9/0004 Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
• CPC Class Codes: A61K 9/1075 Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers A61K9/0026 takes precedence
• CPC Class Codes: A61K 9/1617 Organic compounds, e.g. phospholipids, fats
• CPC Class Codes: A61K 9/1623 Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 5/06 of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Abstract

A liquid composition in an osmotic drug delivery system and a dosage form in an osmotic drug delivery system is disclosed comprising an amphiphilic molecule, a non-aqueous liquid solvent, and a pharmaceutically active agent.

Claims

1. A liquid composition in an osmotic drug delivery system comprising an amphiphilic molecule, a non-aqueous liquid solvent, and a pharmaceutically active agent.

2. The composition of claim 1 wherein the amphiphilic molecule is selected from lipid, surfactant, amphiphilic block polymer, or amphiphilic proteins or peptides.

3. The composition of claim 2 wherein the lipid is selected from saturated lipid, unsaturated lipid, neutral lipid, anionic lipid, cationic lipid, natural lipid or synthetic lipid.

4. The composition of claim 1, wherein said pharmaceutically active agent is suspended in a particle within said liquid composition.

5. The composition of claim 3, wherein the lipid is selected from phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylglycerol (PG), phosphatidylinositol (PI), phosphatidylserine (PS), phosphatidic acid (PA), or sphingomyelin (SM).

6. The composition of claim 3, wherein the neutral lipid is selected from dioleoyl phosphatidylcholine (DOPC), dimyritoylphosphatidylcholine (DMPC), dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), egg phosphatidylcholine (egg PC), soy phosphatidylcholine (soy PC), partially or fully hydrogenated phosphatidylcholins (PHSPC or HSPC), palmitoyl-oleoyl phosphatidylcholine (POPC), or stearyloleoylphosphatidylcholine (SOPC).

7. The composition of claim 3, wherein the anionic lipid is selected from dioleoy phosphatidylglycerol (DOPG), dimyritoylphosphatidylglycerol (DMPG), dipalmitoylphosphatidylglycerol (DPPG), or distearoylphosphatidylglycerol (DSPG).

8. The composition of claim 1, wherein the non-aqueous liquid solvent is selected from lauryl lactate (LL), lauryl alcohol (LA), benzyl alcohol (BA), benzyl benzoate (BB), 1:

1 benzyl benzoate;

benzyl alcohol, benzyl alcohol, ethyl hexyl lactate, glycerol formal, tetraglycol (glycofurol;

GF), N-1-methyl-2-pyrrolidone (NMP), dimethyl sulfoxide, (DMSO), polyethyleneglycol (e.g., PEG

     400), triglycerides (triolein, trilaurin, tricarprin, tricaprylin), ethanol, isopropanol, t-butyl alcohol, cyclohexanol, glycerin, glycerol, α

-tocopherol (vitamin E) vegetable oil, sesame oil, soybean oil, cottonseed oil or peanut oil.

9. The composition of claim 1, further comprising polyethyleneglycol (PEG)-lipid compound selected from MPEG-DPPE, mPEG-DMPE, mPEG-DSPE, mPEG-ceramide-DSPE, or mPEG-DS.

10. The composition of claim 1, further comprising block copolymer surfactants selected from Pluronic®

surfactants or Pluronic®

surfactant F-127, or further comprising sorbitan ester structurants selected from sorbitan di-isostearate, sorbitan dioleate, sorbitan monoisostearate, sorbitan monolaurate, sorbitan monooleate, sorbitan monopalmitate, sorbitan monostearate, sorbitan sesqui-isostearate, sorbitan sesquioleate, sorbitan trioleate, sorbitan sesquistearate, sorbitan tri-isostearate, sorbitan tristearate, or sorbitan tristearate.

11. The composition of claim 1, further comprising an anti-oxidant lipid compound selected from vitamin E, α

-tocopherol, or ascorbic acid.

12. The composition of claim 1 wherein the pharmaceutically active agent is selected from a protein, peptide, small molecule drug, lipid drug or nucleic acid drug, DNA drug, RNA drug, antisense drug, ribozyme drug, DNAzyme drug.

13. The composition of claim 1 wherein an amphiphilic molecule weight percent is from about 1 to about 100 weight percent.

14. The composition of claim 1 wherein the non-aqueous liquid solvent weight percent is from about 0 to about 99 weight percent.

15. The composition of claim 1, wherein the composition is a viscous liquid composition.

16. The composition of claim 15 wherein viscosity of the composition is from about 1 to about 100,000 poise.

17. The composition of claim 1 wherein a ratio by weight of amphiphilic molecule to non-aqueous liquid solvent is between about 1 and about 4.

18. The composition of claim 1 wherein the pharmaceutically active agent is combined with sucrose, methionine and citrate in weight ratios of 1 to 2 to 1 to 2.15.

19. The composition of claim 12, wherein the pharmaceutically active agent is selected from biologically or pharmacologically active substance.

20. The composition of claim 19, wherein the pharmaceutically active agent is ω

-interferon, α

-interferon, β

-interferon, γ

-interferon, erythropoietin, human growth hormone, granulocyte macrophage colony stimulating factor (GM-CSF), human growth hormone releasing hormone (huGHRH), insulin, desmopressin, infliximab, antibody or an agent conjugated to a targeting ligand, risperidone, paliperidone, glucagon-like peptide-1 (GLP-1), or bone morphogenic proteins.

21. A dosage form for osmotic drug delivery comprising:

a capsule including a first chamber containing a viscous liquid pharmaceutical composition and a second chamber containing an osmotic agent, said first chamber having an opening through which the pharmaceutical composition can be delivered from the first chamber to a location external of the first chamber;

a movable separating member positioned in the capsule between the first chamber and the second chamber;

a wall of the second chamber including a fluid permeable portion allowing fluid to pass from a surrounding environment into the second chamber; and

an incompressible fluid additive located within the second chamber and substantially surrounding the osmotic agent.

22. The dosage form of claim 21, wherein the viscous liquid pharmaceutical composition comprises an amphiphilic molecule, a non-aqueous liquid solvent, and a pharmaceutically active agent.

23. The dosage form of claim 22 wherein the amphiphilic molecule is selected from lipid, surfactant, amphiphilic block polymer, or amphiphilic proteins or peptides.

24. The dosage form of claim 23 wherein the lipid is selected from saturated lipid, unsaturated lipid, neutral lipid, or anionic lipid.

25. The dosage form of claim 22, wherein said pharmaceutically active agent is suspended in a particle within said liquid composition.

26. The dosage form of claim 24, wherein the lipid is selected from phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylglycerol (PG), phosphosphatidylinositol (PI), phosphatidylserine (PS), phosphatidic acid (PA), or sphingomyelin (SM).

27. The dosage form of claim 24, wherein the neutral lipid is selected from dioleoyl phosphatidylcholine (DOPC), dimyritoylphosphatidylcholine (DMPC), dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), egg phosphatidylcholine (egg PC), soy phosphatidylcholine (soy PC), partially or fully hydrogenated phosphatidylcholins (PHSPC or HSPC), palmitoyl-oleoyl phosphatidylcholine (POPC), or stearyloleoylphosphatidylcholin (SOPC).

28. The dosage form of claim 24, wherein the anionic lipid is selected from dioleoy phosphatidylglycerol (DOPG), dimyritoylphosphatidylglycerol (DMPG), dipalmitoylphosphatidylglycerol (DPPG), or distearoylphosphatidylglycerol (DSPG).

29. The dosage form of claim 22, wherein the non-aqueous liquid solvent is selected from lauryl lactate (LL), lauryl alcohol (LA), benzyl alcohol (BA), benzyl benzoate (BB), 1:

1 benzyl benzoate;

benzyl alcohol, benzyl alcohol, ethyl hexyl lactate, glycerol formal, tetraglycol (glycofurol;

GF), N-1-methyl-2-pyrrolidone (NMP), dimethyl sulfoxide, (DMSO), polyethyleneglycol (e.g., PEG

     400), triglycerides (triolein, trilaurin, tricarprin, tricaprylin), ethanol, isopropanol, t-butyl alcohol, cyclohexanol, glycerin, glycerol, α

-tocopherol (vitamin E) vegetable oil, sesame oil, soybean oil, cottonseed oil or peanut oil.

30. The dosage form of claim 22 wherein the pharmaceutically active agent is selected from a protein, peptide, small molecule drug, lipid drug, or prodrug conjugated to lipid.

31. The dosage form of claim 21 wherein an amphiphilic molecule weight percent is from about 1 to about 100 weight percent.

32. The dosage form of claim 21 wherein a non-aqueous liquid solvent weight percent is from about 0 to about 99 weight percent.

33. The dosage form of claim 21 wherein viscosity of the composition is from about 1 to about 100,000 poise.

34. The dosage form of claim 21 wherein a ratio by weight of amphiphilic molecule to non-aqueous liquid solvent is between about 1 and about 4.

35. The dosage form of claim 21, wherein the osmotic agent is in a tabular form and the fluid additive surrounds the tabular osmotic agent.

36. The dosage form of claim 21, wherein the separating member is a slidable piston.

37. The dosage form of claim 21, wherein the fluid permeable portion is a membrane.

38. The dosage form of claim 21, wherein the osmotic agent is a tablet.

39. The dosage form of claim 21, wherein the fluid additive is a lubricating liquid for preventing freeze-up of the osmotic agent.

40. The dosage form of claim 21, wherein the fluid additive is a gel.

41. The dosage form of claim 21, wherein the fluid additive includes PEG.

42. The dosage form according to claim 21, including at least one gap between an inner surface of the capsule and the osmotic agent, said fluid additive filling the at least one gap to improve start-up time.

43. The dosage form according to claim 21, wherein the osmotic agent includes NaCl and the fluid additive includes PEG.

44. A suspending vehicle in a pump-driven dosage form comprising an amphiphilic molecule, a non-aqueous solvent, and a performance modifier.

45. The suspending vehicle of claim 44 which is substantially non-aqueous.

46. The suspending vehicle of claim 44 wherein the amphiphilic molecule comprises a lipid.

47. The suspending vehicle of claim 46 wherein the lipid is dioleoyl phosphatidylcholine (DOPC), dimyritoylphosphatidylcholine (DMPC), dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), egg phosphatidylcholine (egg PC), soy phosphatidylcholine (soy PC), partially hydrogenated phosphatidylcholins (PHSPC), fully hydrogenated phosphatidylcholins (HSPC), palmitoyl-oleoyl phosphatidylcholine (POPC), or stearyloleoylphosphatidylcholine (SOPC).

48. The suspending vehicle of claim 44 which is substantially free of stiff gels.

49. The suspending vehicle of claim 48 which is substantially free of stiff gels upon contact with an aqueous medium.

50. The suspending vehicle of claim 44 which has improved rheological properties as compared to a suspending vehicle which does not contain the performance modifier.

51. The suspending vehicle of claim 50 which has a change in viscosity of less than or equal to a factor of 10 in combination with a 10% by weight change in amount of the amphiphilic molecule in the suspending vehicle.

52. The suspending vehicle of claim 44 wherein a weight ratio of the non-aqueous solvent to the performance modifier is from about 1:

0.33 to about 1;

0.001.

53. The suspending vehicle of claim 44 wherein a weight ratio of the amphiphilic molecule to the performance modifier is from about 0.67:

1 to about 1.5;

1.

54. The suspending vehicle of claim 44 wherein a weight ratio of the amphiphilic molecule to a combination of the performance modifier and the non-aqueous solvent is from about 0.75:

1 to about 1.22;

1.

55. The suspending vehicle of claim 46 wherein the lipid comprises dioleoyl phosphatidylcholine (DOPC), the non-aqueous solvent comprises α

-tocopherol, and the performance modifier comprises ethanol, sesame oil, ethyl acetate, or combinations thereof.

56. A kit comprising the suspending vehicle of claim 44 and instructions for suspending or dispersing a pharmaceutically active agent therein to create a pharmaceutical suspension.

57. The kit of claim 56 further comprising a dosage form and instructions for loading the dosage form with the pharmaceutical suspension.

58. A method comprising:

identifying an amphiphilic molecule;

identifying a non-aqueous solvent;

identifying a performance modifier;

mixing the amphiphilic molecule, the non-aqueous solvent, and the performance modifier to create a suspending vehicle.

59. The method of claim 58 wherein the performance modifier improves rheological properties of the suspending vehicle as compared to a suspending vehicle which does not contain the performance modifier.

60. The method of claim 58 comprising substantially dissolving or dispersing the amphiphilic molecule in the performance modifier to create a mixture;

and combining the non-aqueous solvent with the mixture to create a suspending vehicle.

61. The method of claim 60 wherein the amphiphilic molecule dissolves more quickly in a combination of the non-aqueous solvent and the performance modifier as compared to dissolution in only the non-aqueous solvent.

62. The method of claim 58 further comprising adding a pharmaceutically active agent to the suspending vehicle to create a pharmaceutical suspension.

63. The method of claim 62 further comprising adding the pharmaceutical suspension to a dosage form.

64. The method of claim 63 wherein the dosage form comprises a first wall that maintains its physical and chemical integrity during the life of the dosage form and is substantially impermeable to a pharmaceutical suspension;

a second wall that is partially permeable to an exterior fluid;

a compartment defined by the first wall and the second wall; and

an exit port in the wall in communication with the compartment; and

wherein the pharmaceutical suspension is positioned within the compartment.

65. The method of claim 64 wherein the dosage form further comprises an osmotic pump.

66. The method of claim 58 further comprising vortexing the mixture.

67. The method of claim 66 further comprising heating the suspending vehicle to a temperature of from about 100°

C. to about 120°

C.

68. A suspension in a pump-driven dosage form comprising a pharmaceutically active agent suspended or dispersed in a suspending vehicle, wherein the suspending vehicle comprises an amphiphilic molecule, a non-aqueous solvent, and a performance modifier.

69. The suspension of claim 68 wherein the suspending vehicle has a viscosity of from about 1 to about 1,000,000 poise.

70. The suspension of claim 69 wherein the viscosity is from about 5 to about 100,000 poise.

71. The suspension of claim 68 wherein the amphiphilic molecule comprises a lipid.

72. The suspension of claim 71 wherein the lipid is dioleoyl phosphatidylcholine (DOPC), dimyritoylphosphatidylcholine (DMPC), dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), egg phosphatidylcholine (egg PC), soy phosphatidylcholine (soy PC), partially hydrogenated phosphatidylcholins (PHSPC), fully hydrogenated phosphatidylcholins (HSPC), palmitoyl-oleoyl phosphatidylcholine (POPC), or stearyloleoylphosphatidylcholine (SOPC).

73. The suspension of claim 71 wherein the lipid comprises dioleoyl phosphatidylcholine (DOPC), the non-aqueous solvent comprises a-tocopherol, and the performance modifier comprises ethanol, sesame oil, ethyl acetate, or combinations thereof.

74. The suspension of claim 73 wherein the pharmaceutically active agent comprises ω

-interferon.

75. The suspension of claim 68 wherein the pharmaceutically active agent comprises ω

-interferon.

76. A dosage form comprising:

a first wall that maintains its physical and chemical integrity during the life of the dosage form and is substantially impermeable to a pharmaceutical suspension;

a second wall that is partially permeable to an exterior fluid;

a compartment defined by the first wall and the second wall;

a pharmaceutical suspension that is positioned within the compartment and comprises an amphiphilic molecule, a non-aqueous solvent, a performance modifier, and a pharmaceutically active agent; and

an exit port in the wall in communication with the compartment.

77. The dosage form of claim 76 further comprising an osmotic pump.

78. The dosage form of claim 76 wherein upon contact with an aqueous medium, the pharmaceutical suspension is flowable through the exit port.

79. The dosage form of claim 77 wherein upon contact with an aqueous medium, the pharmaceutical suspension is flowable through the exit port under a force exerted by the osmotic pump under normal operating conditions.

80. The dosage form of claim 76 wherein the pharmaceutical suspension is substantially free of stiff gels upon contact with an aqueous medium.

81. The dosage form of claim 76 wherein the pharmaceutical suspension is substantially homogeneous for at least 3 months at 37°

C.

82. A method comprising administering the dosage form of claim 76 to a mammal.

83. A kit comprising a dosage form of claim 76 and instructions for administering the dosage form.